Market Overview

Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

NEW HAVEN, Conn., Nov. 9, 2012 /PRNewswire/ --

Event:

HCV Connection Media Briefing

Date:

Monday, November 12

Time:

7:45 a.m. Eastern Standard Time

Where:

Sheraton Boston Hotel; 39 Dalton Street, Boston, MA 02199;


Also available by Webcast (link will be provided upon request)

The content of the media briefing will include the following themes and information:

  • An overview of HCV and the current epidemic worldwide
  • A compelling historical and scientific context for understanding the new era of HCV therapies and the emergence of patient-guided therapy
  • A brief review of first and second-generation direct-acting antiviral therapies, including important new developments in drug discovery
  • A detailed look at Achillion Pharmaceutical's portfolio aimed at curing HCV in a complex and diverse patient population

Following the briefing there will be a Question & Answer session with leading experts in HCV including:

  • Fred Poordad, MD, Chief Medical Officer of the Texas Liver Institute and Alamo Medical Research, San Antonio, Texas
  • Andrew Muir, MD, Director, Gastroenterology and Hepatology Research Group, Duke Clinical Research Institute, Durham, North Carolina
  • The session will also be moderated by Lisa Stark of ABC News

Achillion (Nasdaq: ACHN) is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have identified and advanced multiple therapeutic compounds, many with novel mechanisms or attributes. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C (HCV) and resistant bacterial infections. Please visit www.achillion.com for additional information.

SOURCE Achillion Pharmaceuticals, Inc.

 

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters